A Study of FX-909 in Patients with Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors CancerOral Drug AdministrationAdvanced Urothelial CarcinomaOpen Label
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Flare Therapeutics Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT05929235
- Locations
- 🇺🇸
HonorHealth, Scottsdale, Arizona, United States
🇺🇸Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸Mass General Cancer Center, Boston, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath